



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/750,410	12/28/2000	Gloria C. Li	55672-A-PCT-US/ JPW/AJM/M	6916
57539	7590	01/23/2007	EXAMINER	
COOPER & DUNHAM LLP 1185 AVENUE OF THE AMERICAS NEW YORK, NY 10036			ZARA, JANE J	
		ART UNIT	PAPER NUMBER	
		1635		
		MAIL DATE	DELIVERY MODE	
		01/23/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

**Advisory Action
Before the Filing of an Appeal Brief**

Application No.	09/750,410	Applicant(s)	LI ET AL.
Examiner	Jane Zara	Art Unit	1635

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 28 December 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

- a) The period for reply expires _____ months from the mailing date of the final rejection.
 b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. The Notice of Appeal was filed on 29 December 2006. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
- (a) They raise new issues that would require further consideration and/or search (see NOTE below);
 - (b) They raise the issue of new matter (see NOTE below);
 - (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 - (d) They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
 5. Applicant's reply has overcome the following rejection(s): _____.
 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: 1, 15, 16 and 18-22.

Claim(s) withdrawn from consideration: _____.

AFFIDAVIT OR OTHER EVIDENCE

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attached.
 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). _____.
 13. Other: _____.

JANE ZARA, PH.D.
PRIMARY EXAMINER

83
TC 1600

Attachment

The instant invention remains rejected for the reasons of record set forth in the Office action mailed 6-26-06. The proposed amendments will not be entered because they introduce limitations that require a new search and there is no reason that these limitations were not presented earlier in the prosecution. Furthermore, the limitations do not place the application or claims in better form for allowance. The invention comprising compositions and methods of in vitro inhibition of expression of the target gene human Ku70 comprising the administration of antisense would have been obvious to one of ordinary skill in the art at the time the invention was made - whether the antisense administered was full length antisense or was a shorter oligonucleotide.

As set forth in the final Office action mailed 6-26-06, Takiguchi teaches the DNA-dependent protein kinase (DNA-PK) comprising Ku70, Ku80 and the DNA-PK catalytic subunit, which DNA-PK functions in DNA double-strand break repair (see 1st & 3rd full paragraph on p. 129). Takiguchi also teaches that the Ku70/80 heterodimer portion of the DNA-PK binds with high affinity to the end of double stranded DNA, and to a single stranded DNA transition (see 2nd full paragraph on p. 129), and recruits and activates the DNA catalytic subunit of the DNA-PK (see 3rd full paragraph on p. 129). Takiguchi teaches the role of Ku70 in DNA double strand repair (see bridging paragraph, pp. 133-134). Reeves et al (J. Biol. Chem., Vol. 264(9): 5047-5052, 1989) teach the polynucleotide sequence encoding human DNA-PK subunit Ku70, and Ku70's binding to the ends of double stranded DNA in a complex with Ku80 (see especially figure 4 on p. 5050 and the text on p. 5047). Milner et al (Nature Biotech. 15: 537-541, 1997) teach

Art Unit: 1635


methods of designing and testing antisense for their ability to specifically hybridize and inhibit the expression of a target nucleic acid of known nucleotide sequence in vitro (See especially figures 5-7 on pages 539-540).

It would have been obvious to one of ordinary skill in the art to design and utilize antisense to inhibit the expression of Ku70 in vitro because its nucleotide sequence had been taught previously by Reeves et al, and Milner et al teach the ability to design and assess antisense molecules for their ability to inhibit the expression of a target gene of known nucleotide sequence in vitro using routine screening assays that are well known in the art (see Milner at pages 539-540). Milner et al additionally teach methods of designing and evaluating antisense of various sizes, including those which target different regions of a target gene of previously disclosed sequence for their ability to inhibit a target gene in vitro. One of ordinary skill in the art would have expected that the methods of designing and assessing antisense molecules for inhibiting a target gene of known sequence, which were taught by Milner et al, to be routine for a previously characterized target gene, would successfully be used to identify numerous antisense oligonucleotides human DNA dependent protein kinase subunits, including Ku70.

One of ordinary skill in the art would have been motivated to target and inhibit the expression of the various subunits of DNA-PK, including Ku70, in order to increase a target cell's sensitivity to DNA damaging agents because Takiguchi et al teach the relationship between increasing cell radiosensitivity or loss of DNA repair function, and loss of functional DNA-PK. One of ordinary skill in the art would have been motivated to

Art Unit: 1635

inhibit the expression of Ku70 in order to increase a target cell's sensitivity to DNA repair because it was well known in the art at the time of the invention that Ku 70 is involved in double stranded DNA repair and it was also well known that strand repair occurs in cells following DNA damage (e.g. strand breaks). One of ordinary skill in the art would have expected that a cancer cell would undergo DNA repair after its exposure to DNA damaging agents. And one of ordinary skill in the art would be motivated to undermine a cancer cell's ability to repair DNA after treating it with DNA damaging agents in order to eventually undermine that cancer's ability to survive. For these reasons and the reasons set forth in the prior Office action mailed 6-26-06, the instant claims stand rejected.

The signature is handwritten in black ink. It consists of the letters "JZ" followed by "Jane" written in cursive script. Below the name is the number "1600".

JANE ZARA, PH.D.
PRIMARY EXAMINER